GeneDx Holdings (WGS) Other Accumulated Expenses (2020 - 2026)

GeneDx Holdings has disclosed Other Accumulated Expenses across 7 years of filings, most recently posting $35.9 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 46.4% year-over-year to $35.9 million; the TTM figure through Mar 2026 stood at $35.9 million (up 46.4% YoY), while the FY2025 annual figure was $46.9 million, up 128.6% from the prior year.
• Other Accumulated Expenses fell to $35.9 million in Q1 2026, from $46.9 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for WGS reached as high as $81.6 million in Q2 2022 and fell as low as $727000.0 in Q3 2024.
• The 5-year median for Other Accumulated Expenses is $23.4 million (2022), against an average of $30.4 million.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses tumbled 96.67% — and 2025, when it soared 4419.67%.
• A 5-year view of Other Accumulated Expenses shows it stood at $49.7 million in 2022, then tumbled by 67.13% to $16.3 million in 2023, then advanced by 25.48% to $20.5 million in 2024, then soared by 128.6% to $46.9 million in 2025, then decreased by 23.28% to $35.9 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $35.9 million, $46.9 million, and $32.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.